Our data suggests that inhibition of HDAC activity can control Pa-LPS induced lung disease by modulating NFκB-mediated inflammatory signaling, neutrophil chemotaxis and T-reg-activation by CFTR-dependent and/or independent mechanisms. This evidence concerns the gene NFKB1 and lung disorder.